Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 7/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18031195 | 0.81 | MTOR (0.41) | NUDT1GRM4NOS3NOS1NOS2 | |
| SCHEMBL12316236 | 0.80 | P2RX3 (0.47) | P2RX3P2RX2DHFR | |
| SCHEMBL12896015 | 0.77 | CCR1 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL21389722 | 0.77 | BCL6 (0.43) | P2RX3P2RX2DHFR | |
| SCHEMBL558803 | 0.77 | P2RX3 (0.40) | GRM4P2RX3P2RX2DHFR | |
| SCHEMBL20049808 | 0.77 | P2RX3 (0.40) | NUDT1GRM4P2RX3P2RX2DHFR | |
| SCHEMBL31722144 | 0.77 | P2RX3 (0.40) | GRM4P2RX3P2RX2DHFR | |
| SCHEMBL14997542 | 0.76 | APLNR (0.34) | — | |
| SCHEMBL25928373 | 0.74 | CCR1 (0.35) | — | |
| SCHEMBL25619059 | 0.74 | CCR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20170050972-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-02-23 | — | — | US | disclosed |
| WO-2008032171-A1 | DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | MATRIX LABORATORIES LTD. (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | NUDT1 1171/4885GRM4 4456/4885P2RX3 2622/4885 |
| US-20170050972-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | NUDT1 1349/4885GRM4 3726/4885P2RX3 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.